Stem cells and Bronchopulmonary Dysplasia - The five questions: Which cells, when, in which dose, to which patients via which route?

Müller, Martin; Kramer, Boris W (2017). Stem cells and Bronchopulmonary Dysplasia - The five questions: Which cells, when, in which dose, to which patients via which route? Paediatric respiratory reviews, 24, pp. 54-59. Elsevier 10.1016/j.prrv.2016.12.003

[img]
Preview
Text
28162941.pdf - Published Version
Available under License Publisher holds Copyright.

Download (585kB) | Preview

Preterm birth is the leading cause of death in newborns and children. Despite advances in perinatology, immature infants continue to face serious risks such chronic respiratory impairment from bronchopulmonary dysplasia (BPD). Current treatment options are insufficient and novel approaches are desperately needed. In recent years stem cells have emerged as potential candidates to treat BPD with mesenchymal stem/stromal cells (MSCs) being particularly promising. MSCs originate from several stem cell niches including bone marrow, skin, or adipose, umbilical cord, and placental tissues. Although the first MSCs clinical trials in BPD are ongoing, multiple questions remain open. In this review, we discuss the question of the optimal cell source (live cells or cell products), route and timing of the transplantation. Furthermore, we discuss MSCs possible capacities including migration, homing, pro-angiogenesis, anti-inflammatory, and tissue-regenerative potential as well.

Item Type:

Journal Article (Review Article)

Division/Institute:

04 Faculty of Medicine > Department of Gynaecology, Paediatrics and Endocrinology (DFKE) > Clinic of Gynaecology

UniBE Contributor:

Müller, Martin (A)

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1526-0542

Publisher:

Elsevier

Language:

English

Submitter:

Monika Zehr

Date Deposited:

22 Mar 2018 11:04

Last Modified:

29 Mar 2023 23:35

Publisher DOI:

10.1016/j.prrv.2016.12.003

PubMed ID:

28162941

Uncontrolled Keywords:

Bronchopulmonary dysplasia mesenchymal stem cell transplantation outcomes paracrine immunomodulation physiologic actions

BORIS DOI:

10.7892/boris.111113

URI:

https://boris.unibe.ch/id/eprint/111113

Actions (login required)

Edit item Edit item
Provide Feedback